AIMS: Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response. The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients. MATERIALS AND METHODS: A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy. In total, 42 patients were enrolled. RESULTS: Talabostat was well tolerated. Two patients achieved a partial response and one achieved a complete response. CONCLUSION: There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.
AIMS: Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response. The aim of this study was to determine the efficacy and safety of talabostat in NSCLCpatients. MATERIALS AND METHODS: A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy. In total, 42 patients were enrolled. RESULTS:Talabostat was well tolerated. Two patients achieved a partial response and one achieved a complete response. CONCLUSION: There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.
Authors: Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry Journal: J Immunother Date: 2013-10 Impact factor: 4.456
Authors: Hailey A Clancy; Hong Sun; Lisa Passantino; Thomas Kluz; Alexandra Muñoz; Jiri Zavadil; Max Costa Journal: Metallomics Date: 2012-06-19 Impact factor: 4.526
Authors: Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans Journal: Future Med Chem Date: 2013-04 Impact factor: 3.808
Authors: W Nathaniel Brennen; D Marc Rosen; Hao Wang; John T Isaacs; Samuel R Denmeade Journal: J Natl Cancer Inst Date: 2012-08-21 Impact factor: 13.506
Authors: Renee N Donahue; Brynn B Duncan; Terry J Fry; Barry Jones; William W Bachovchin; Christopher P Kiritsy; Jack H Lai; Wengen Wu; Peng Zhao; Yuxin Liu; Kwong-Yok Tsang; James W Hodge Journal: Vaccine Date: 2014-04-13 Impact factor: 3.641
Authors: Ainhoa Arina; Christian Idel; Elizabeth M Hyjek; Maria-Luisa Alegre; Ying Wang; Vytautas P Bindokas; Ralph R Weichselbaum; Hans Schreiber Journal: Proc Natl Acad Sci U S A Date: 2016-06-17 Impact factor: 11.205
Authors: W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs Journal: Immunotherapy Date: 2020-11-05 Impact factor: 4.196